(E)-5-[2,6-dimethyl-8-(2,6,6-trimethyl-1-cyclohexen-1-yl)octa-1,3,5,7-tetraen-1-yl]tetrazole | 74597-00-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (E)-5-[2,6-dimethyl-8-(2,6,6-trimethyl-1-cyclohexen-1-yl)octa-1,3,5,7-tetraen-1-yl]tetrazole
• 英文别名: 5-(2,6-Dimethyl-8-(2,6,6-trimethylcyclohexen-1-yl)-1,3,5,7-octatetraen-1-yl)tetrazole,trans；5-[(1E,3E,5E,7E)-2,6-dimethyl-8-(2,6,6-trimethylcyclohexen-1-yl)octa-1,3,5,7-tetraenyl]-2H-tetrazole
• CAS: 74597-00-5
• 化学式: C₂₀H₂₈N₄
• 分子量: 324.469
• InChiKey: XXCOKGZUOMUVEP-YCNIQYBTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  9-trans-13-trans-dimethyl-7-(1,1,5-trimethyl-5-cyclohexen-6-yl)-7,9,11,13-nonatetraene-15-nitrile 在 三氯化铝 、 sodium azide 作用下， 以 四氢呋喃 为溶剂， 反应 240.0h， 以41%的产率得到(E)-5-[2,6-dimethyl-8-(2,6,6-trimethyl-1-cyclohexen-1-yl)octa-1,3,5,7-tetraen-1-yl]tetrazole
  参考文献：
  名称：

  维甲酸类似物。合成和潜在的癌症化学预防剂。

  摘要：

  视黄酸的类似物已被合成为潜在的针对上皮癌的化学预防剂。（E）-9-（2-降冰片烯基）-3,7-二甲基壬娜-2,4,6,8-四烯酸酯（9），（E）-3,7-二甲基-9-（2-乙基-6） 1,6-二甲基-1-环己烯-1-基）壬二-2,4,6,8-丁烯酸（25）和2-（2'-甲氧基乙氧基）视黄酸乙酯（26）在抑制甲壳素方面表现出良好的活性。肿瘤启动子诱导的小鼠表皮鸟氨酸脱羧酶测定。（E）-1-（3-乙酰氧基苯基）-4-甲基-6-（2,6,6-三甲基-1-环己烯-1-基）hexa1,3,5-三烯（34）的活性低。（E）-5- [2,6-二甲基-8-（2,6,6-三甲基-1-环己烯-1-基）辛基-1,3,5,7-四烯-1-基]四唑（ 40）不活跃。

  DOI：

  10.1021/jm00183a010

文献信息

• Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
  申请人：Beth Israel Deaconess Medical Center, Inc.

  公开号：US10548864B2

  公开（公告）日：2020-02-04

  The invention features all-trans retinoic acid (ATRA)-related compounds capable of associating with Pin1 and methods of treating a proliferative disorder characterized by elevated Pin1 marker levels, Pin1 degradation, and/or reduced Pin1 Ser71 phosphorylation in a subject by administering an ATRA-related compound. The invention also features methods of treating proliferative disorders, autoimmune diseases, and addiction conditions (e.g., diseases, disorders, and conditions characterized by elevated Pin1 marker levels) by administering an ATRA-related compound in combination with another therapeutic compound.

  本发明的特征是能够与Pin1结合的全反式维甲酸（ATRA）相关化合物，以及通过施用ATRA相关化合物治疗以Pin1标记物水平升高、Pin1降解和/或Pin1 Ser71磷酸化降低为特征的增殖性疾病的方法。本发明的另一个特点是通过施用 ATRA 相关化合物与另一种治疗化合物联合治疗增殖性疾病、自身免疫性疾病和成瘾病症（例如，以 Pin1 标记水平升高为特征的疾病、病症和病症）的方法。
• Arsenic trioxide for treatment of PIN1-associated disorders
  申请人：Beth Israel Deaconess Medical Center, Inc.

  公开号：US10980835B2

  公开（公告）日：2021-04-20

  The present invention relates to the treatment of Pin1-associated disorders (e.g., disorders characterized by elevated Pin1 activity) with arsenic trioxide, optionally in combination with a retinoic acid compound. Pin1-associated disorders may include, for example, proliferative disorders (e.g., cancers), inflammatory conditions, and autoimmune disorders associated with aberrant levels of Pin1 activity.

  本发明涉及用三氧化二砷治疗Pin1相关疾病（例如，以Pin1活性升高为特征的疾病），可选择与维甲酸化合物联合使用。Pin1相关疾病可包括与Pin1活性异常水平相关的增殖性疾病（如癌症）、炎症和自身免疫性疾病等。
• ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS
  申请人：Lu Kun Ping

  公开号：US20180064666A1

  公开（公告）日：2018-03-08

  The invention features all-trans retinoic acid (ATRA)-related compounds capable of associating with Pin1 and methods of treating a proliferative disorder characterized by elevated Pin1 marker levels, Pin1 degradation, and/or reduced Pin1 Ser71 phosphorylation in a subject by administering an ATRA-related compound. The invention also features methods of treating proliferative disorders, autoimmune diseases, and addiction conditions (e.g., diseases, disorders, and conditions characterized by elevated Pin1 marker levels) by administering an ATRA-related compound in combination with another therapeutic compound.
• ARSENIC TRIOXIDE FOR TREATMENT OF PIN1-ASSOCIATED DISORDERS
  申请人：Beth Israel Deaconess Medical Center, Inc.

  公开号：US20180153934A1

  公开（公告）日：2018-06-07

  The present invention relates to the treatment of Pin1-associated disorders (e.g., disorders characterized by elevated Pin1 activity) with arsenic trioxide, optionally in combination with a retinoic acid compound. Pin1-associated disorders may include, for example, proliferative disorders (e.g., cancers), inflammatory conditions, and autoimmune disorders associated with aberrant levels of Pin1 activity.
• [EN] ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS<br/>[FR] COMPOSÉS APPARENTÉS À ATRA AMÉLIORÉS POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES, DE MALADIES AUTO-IMMUNES ET D'AFFECTIONS ADDICTIVES
  申请人：BETH ISRAEL DEACONESS MEDICAL CT INC

  公开号：WO2016145186A1

  公开（公告）日：2016-09-15

  The invention features all-trans retinoic acid (ATRA)-related compounds capable of associating with Pin1 and methods of treating a proliferative disorder characterized by elevated Pin1 marker levels, Pin1 degradation, and/or reduced Pin1 Ser71 phosphorylation in a subject by administering an ATRA-related compound. The invention also features methods of treating proliferative disorders, autoimmune diseases, and addiction conditions (e.g., diseases, disorders, and conditions characterized by elevated Pin1 marker levels) by administering an ATRA-related compound in combination with another therapeutic compound.